inclusion criteria: phase i (abbreviated): * healthy males or females, ages 18 to 55 (inclusive) at the time of screening. * negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. * females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. * subjects in general good health with no chronic disease nor consumes chronic medication in the opinion of the investigator as determined by medical history, vital signs and a physical examination. * no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. * negative hiv, hepatitis b and hepatitis c serology tests. * normal oral temperature, normal sinus rhythm, pulse rate no greater than 100 beats per minute and normal systolic blood pressure (below 140/90 mmhg) * must be willing to forgo blood donation during the blood drawing phase of the study. * must agree not to enroll in another study of an investigational agent prior to completion of the study. * subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. * ability to provide informed consent. phase ii (abbreviated): * males or females, ages 18 to 85 (inclusive) at the time of screening. * negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. * females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. male must agree to avoid sperm donation from time of first injection through 90 days following last injection. * no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. * must be willing to forgo blood donation during the blood drawing phase of the study * must agree not to enroll in another study of an investigational agent prior to completion of the study. * normal oral temperature, pulse rate no greater than 100 beats per minute (sinus rhythm) and controlled blood pressure (in the case of hypertensives under treatment, below 140/90 mmhg). * subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. * ability to provide informed consent.

inclusion criteria: phase i (abbreviated): * healthy males or females, ages 18 to 55 (inclusive) at the time of screening. * negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. * females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. * subjects in general good health with no chronic disease nor consumes chronic medication in the opinion of the investigator as determined by medical history, vital signs and a physical examination. * no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. * negative hiv, hepatitis b and hepatitis c serology tests. * normal oral temperature, normal sinus rhythm, pulse rate no greater than 100 beats per minute and normal systolic blood pressure (below 140/90 mmhg) * must be willing to forgo blood donation during the blood drawing phase of the study. * must agree not to enroll in another study of an investigational agent prior to completion of the study. * subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. * ability to provide informed consent. phase ii (abbreviated): * males or females, ages 18 to 85 (inclusive) at the time of screening. * negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. * females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. male must agree to avoid sperm donation from time of first injection through 90 days following last injection. * no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. * must be willing to forgo blood donation during the blood drawing phase of the study * must agree not to enroll in another study of an investigational agent prior to completion of the study. * normal oral temperature, pulse rate no greater than 100 beats per minute (sinus rhythm) and controlled blood pressure (in the case of hypertensives under treatment, below 140/90 mmhg). * subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. * ability to provide informed consent.

inclusion criteria: phase i (abbreviated): - healthy males or females, ages 18 to 55 (inclusive) at the time of screening. - negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. - females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. - subjects in general good health with no chronic disease nor consumes chronic medication in the opinion of the investigator as determined by medical history, vital signs and a physical examination. - no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. - negative hiv, hepatitis b and hepatitis c serology tests. - normal oral temperature, normal sinus rhythm, pulse rate no greater than 100 beats per minute and normal systolic blood pressure (below 140/90 mmhg) - must be willing to forgo blood donation during the blood drawing phase of the study. - must agree not to enroll in another study of an investigational agent prior to completion of the study. - subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. - ability to provide informed consent. phase ii (abbreviated): - males or females, ages 18 to 85 (inclusive) at the time of screening. - negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. - females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. male must agree to avoid sperm donation from time of first injection through 90 days following last injection. - no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. - must be willing to forgo blood donation during the blood drawing phase of the study - must agree not to enroll in another study of an investigational agent prior to completion of the study. - normal oral temperature, pulse rate no greater than 100 beats per minute (sinus rhythm) and controlled blood pressure (in the case of hypertensives under treatment, below 140/90 mmhg). - subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. - ability to provide informed consent.

inclusion criteria: phase i (abbreviated): - healthy males or females, ages 18 to 55 (inclusive) at the time of screening. - negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. - females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. - subjects in general good health with no chronic disease nor consumes chronic medication in the opinion of the investigator as determined by medical history, vital signs and a physical examination. - no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. - negative hiv, hepatitis b and hepatitis c serology tests. - normal oral temperature, normal sinus rhythm, pulse rate no greater than 100 beats per minute and normal systolic blood pressure (below 140/90 mmhg) - must be willing to forgo blood donation during the blood drawing phase of the study. - must agree not to enroll in another study of an investigational agent prior to completion of the study. - subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. - ability to provide informed consent. phase ii (abbreviated): - males or females, ages 18 to 85 (inclusive) at the time of screening. - negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. - females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. male must agree to avoid sperm donation from time of first injection through 90 days following last injection. - no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. - must be willing to forgo blood donation during the blood drawing phase of the study - must agree not to enroll in another study of an investigational agent prior to completion of the study. - normal oral temperature, pulse rate no greater than 100 beats per minute (sinus rhythm) and controlled blood pressure (in the case of hypertensives under treatment, below 140/90 mmhg). - subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. - ability to provide informed consent.

inclusion criteria: phase i (abbreviated): - healthy males or females, ages 18 to 55 (inclusive) at the time of screening. - negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. - females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. - subjects in general good health with no chronic disease nor consumes chronic medication in the opinion of the investigator as determined by medical history, vital signs and a physical examination. - no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. - negative hiv, hepatitis b and hepatitis c serology tests. - normal oral temperature, normal sinus rhythm, pulse rate no greater than 100 beats per minute and normal systolic blood pressure (below 140/90 mmhg) - must be willing to forgo blood donation during the blood drawing phase of the study. - must agree not to enroll in another study of an investigational agent prior to completion of the study. - subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. - ability to provide informed consent. phase ii (abbreviated): - males or females, ages 18 to 85 (inclusive) at the time of screening. - negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. - females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. - no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. - must be willing to forgo blood donation during the blood drawing phase of the study - must agree not to enroll in another study of an investigational agent prior to completion of the study. - normal oral temperature, pulse rate no greater than 100 beats per minute (sinus rhythm) and controlled blood pressure (in the case of hypertensives under treatment, below 140/90 mmhg). - subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. - ability to provide informed consent.

inclusion criteria: phase i (abbreviated): - healthy males or females, ages 18 to 55 (inclusive) at the time of screening. - negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. - females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. - subjects in general good health with no chronic disease nor consumes chronic medication in the opinion of the investigator as determined by medical history, vital signs and a physical examination. - no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. - negative hiv, hepatitis b and hepatitis c serology tests. - normal oral temperature, normal sinus rhythm, pulse rate no greater than 100 beats per minute and normal systolic blood pressure (below 140/90 mmhg) - must be willing to forgo blood donation during the blood drawing phase of the study. - must agree not to enroll in another study of an investigational agent prior to completion of the study. - subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. - ability to provide informed consent. phase ii (abbreviated): - males or females, ages 18 to 85 (inclusive) at the time of screening. - negative pcr and no presence of elisa antibody titers to sars-cov-2 at screening. - females of childbearing potential and males must be willing to use effective methods of contraception such as hormones (ocp, oral contraceptive pill), condom or occlusive cap with spermicidal agents, intrauterine device (iud) or intrauterine system (ius) from at least 14 days prior to vaccination through 90 days following last injection. - no clinically significant abnormalities in hematology, blood chemistry, or urinalysis laboratory tests at screening. - must be willing to forgo blood donation during the blood drawing phase of the study - must agree not to enroll in another study of an investigational agent prior to completion of the study. - normal oral temperature, pulse rate no greater than 100 beats per minute (sinus rhythm) and controlled blood pressure (in the case of hypertensives under treatment, below 140/90 mmhg). - subjects must be able to understand the requirements of the study and must be accessible and willing to comply with the study procedures even under lock down conditions. - ability to provide informed consent.